Current Fungal Infection Reports

, Volume 7, Issue 2, pp 96–109 | Cite as

Treatment of Invasive Candida Infections in the Neonatal Intensive Care Unit

Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)


Invasive Candida infections are a leading cause of morbidity and mortality in the neonatal intensive care unit (NICU). Extremely preterm and very low birth weight infants are at the highest risk of infection. There are currently no antifungal agents that have FDA-labeling for the treatment of invasive candidiasis in the neonatal population. Based on the current IDSA guidelines, amphotericin and fluconazole are considered first-line options for neonatal candidiasis. The newer antifungal agents (i.e., echinocandins and voriconazole) are currently considered second-line or salvage therapy; however, evidence supporting their use is emerging. This review focuses on the supporting evidence for the selection of antifungal agents for treatment of invasive Candida infections in the NICU.


Candida Neonate Infant Antifungal 


Conflict of Interest

Megan G. Andrews declares that she has no conflict of interest.

Roshni Patel declares that she has no conflict of interest.

Jamie Miller declares that she has no conflict of interest.


No financial support was provided for this study


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Chitnis AS, Magill SS, Edwards JR, et al. Trends in Candida central line-associated bloodstream infections among NICUs, 1999–2009. Pediatr. 2012;130:e46–52. This study provides the most current trends of Candida spp. bloodstream infections in US NICU’s from 1999–2009. The authors report a decline in the incidence of Candida infections among NICU patients. C. albicans and C. parapsilosis were the most common species identified.CrossRefGoogle Scholar
  2. 2.
    Liebovitz E. Strategies for the prevention of neonatal candidiasis. Pediatr Neonatol. 2012;53:83–9.CrossRefGoogle Scholar
  3. 3.
    Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 19th ed. Hudson: Lexi-Comp, Inc; 2012.Google Scholar
  4. 4.
    Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice? Curr Opin Infect Dis 2011;24:163–71.Google Scholar
  5. 5.
    Prasad PA, Coffin SE, Leckerman KH, et al. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J. 2008;27:1083–8.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Pappas PG, Kauffman CA, Benjamin DK, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. These guidelines established by the Infectious Diseases Society of America are the most current guidelines addressing the management of invasive candidiasis in several patient populations. There is a section devoted specifically to the treatment of neonatal candidiasis.PubMedCrossRefGoogle Scholar
  7. 7.
    Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. Pedaitr. 1990;116:791–7.CrossRefGoogle Scholar
  8. 8.
    Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988;113:559–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Starke JR, Mason Jr EO, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987;155:766–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neontates. Antimicrob Agents Chemother. 2005;49:5092–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Jeon GW, Koo SH, Lee JH, et al. A comparison of Am Bisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J. 2007;48:619–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52:663–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B, et al. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol. 2003;20:153–63.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012;31:439–43. This recent retrospective, database review was the first to report an increased mortality rate in neonates treated with liposomal amphotericin formulations versus amphotericin dexoycholate or fluconazole.PubMedCrossRefGoogle Scholar
  15. 15.
    Cetin H, Yalaz M, Akisu M, et al. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia. Pediatr Int. 2005;47:676–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis. 2003;22:603–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Adler-Chohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal candidiasis. Arch Dis Child Fetal Neonatal Ed. 2001;84:F131–3.CrossRefGoogle Scholar
  18. 18.
    Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection. 2000;28:223–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis. 2003;36:630–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed December 2012.Google Scholar
  21. 21.
    Wade KC, Benjamin Jr DK, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28:717–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011;30(5):375–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Wenzl TG, Schefels J, Hornchen H, et al. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr. 1998;157(8):661–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Huttova M, Hartmanova I, Kralinsky K, et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J. 1998;17(11):1012–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Wainer S, Cooper PA, Gouws H, et al. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J. 1997;16(8):763–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Fasano C, O'Keeffe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis. 1994;13(4):351–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J. 1996;15(12):1107–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Schwarze R, Penk A, Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res. 2000;5(5):203–8.PubMedGoogle Scholar
  29. 29.
    Huang YC, Lin TY, Lien RI, et al. Fluconazole therapy in neonatal candidemia. Am J Perinatol. 2000;17(8):411–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Muldrew KM, Maples HD, Stowe CD, Jacobs RF. Intravenous voriconazole therapy in a preterm infant. Pharmacother. 2005;25:893–8.CrossRefGoogle Scholar
  32. 32.
    Turan O, Ergenekon E, Hirfanoglu IM, et al. Combination antifungal therapy with voriconazole for persistent candidemia in very low birth weight neonates. Turk J Pediatr. 2011;53:19–26.PubMedGoogle Scholar
  33. 33.
    Kohli V, Taneja V, Sachdev P, Joshi R. Voriconazole in newborns. Ind Pediatr. 2008;45:236–8.Google Scholar
  34. 34.
    • Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009;53(3):869–75. This is the first prospective PK study of caspofungin in neonates and infants. Caspofungin dosed at 25 mg/m2 in infants provides a similar plasma exposure to that of adults receiving 50 mg/day. Slight elevations in trough concentrations were noted in neonates and infants, compared to the adult population.PubMedCrossRefGoogle Scholar
  35. 35.
    Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23(12):1093–7.PubMedGoogle Scholar
  36. 36.
    Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol. 2005;25(12):770–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Manzar S, Kamat M, Pyati S. Caspofungin for refractory candidemia in neonates. Pediatr Infect Dis J. 2006;25(3):282–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Natale F, Castronovo A, Regoli D, et al. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. Pediatr Infect Dis J. 2009;28(5):452.PubMedGoogle Scholar
  39. 39.
    Yalaz M, Akisu M, Hilmioglu S, et al. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses. 2006;49:242–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Haase R, Kreft B, Foell J, et al. Successful treatment of Candida albicans septicemia in a preterm infant with severe congenital ichthyosis (Harlequin baby). Pediatr Dermatol. 2009;26(5):575–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Smith PB, Steinbach WJ, Cotton CM, et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol. 2007;27:127–9.PubMedCrossRefGoogle Scholar
  42. 42.
    • Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr. 2012;58(1):25–30. This study randomized, double-blind trial to compare use of caspofungin and amphotericin B in neonates with invasive candidiasis. Caspofungin treated patients had a statistically significant increase in efficacy rate and lower incidence of adverse effects. Based on their results, the authors propose that caspofungin is an appropriate alternative to amphotericin for the treatment of invasive candidiasis in neonates.PubMedCrossRefGoogle Scholar
  43. 43.
    Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Benjamin DK, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93–9.PubMedCrossRefGoogle Scholar
  46. 46.
    • Hope WW, Smith B, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633–7. This study is the largest micafungin PK study in neonates. The authors combined the data from three smaller PK studies with doses ranging from 0.75–15 mg/kg. Monte Carlo simulations were performed and the authors recommend dosing micafungin at 10 mg/kg/day to achieve adequate CNS concentrations in neonates.PubMedCrossRefGoogle Scholar
  47. 47.
    Ascher S, Smith PB, Benjamin DK. Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf. 2011;10:281–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Kawaguchi C, Arai I, Yasuhara H, et al. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int. 2009;51:220–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Natarjan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol. 2009;29:738–43.CrossRefGoogle Scholar
  50. 50.
    Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820–6.PubMedCrossRefGoogle Scholar
  51. 51.
    • Cohen-Wolkowiez M, Benjamin Jr DK, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmcol Ther. 2011;89:702–7. This is the first PK study of anidulafungin in infants and neonates. This study demonstrated that anidulafungin doses of 1.5 mg/kg/day achieved a similar area under the curve to children receiving the same dose.CrossRefGoogle Scholar
  52. 52.
    Benjamin Jr DK, Discoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Varisco BM, Benner KW, Prabhakaran P. Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. Ann Pharmacother. 2009;43:1907–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Pahud BA, Greenhow TL, Piecuch B, et al. Preterm neonates with candidal brain microabcesses: a case series. J Perinatol. 2009;29:323–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Faix RG, Feick HJ, Frommelt P, et al. Successful medical treatment of Candida parapsilosis endocardidits in a premature infant. Am J Perinatol. 1990;7:272–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Zenker PN, Rosenberg EM, Van Dyke RB, et al. Successful medical treatment of presumed Candida endocarditis in critically ill infants. J Pediatr. 1991;119:72–7.Google Scholar
  57. 57.
    Freydiere AM, Piens MA, Andre JM, et al. Successful treatment of Candida glabrata peritonitis with fluconazole plus flucytosine in a premature infant following in vitro fertilization. Eur J Clin Microbiol Infect Dis. 2005;24:704–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Wald M, Lawrenz K, Kretzer V, et al. A very low birth weight infant with Candida nephritis with fungal balls. Full recovery after pyletomy and antifungal combination therapy. Eur J Pediatr. 2003;162:642–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Brecht M, Clerihew L, McGuire W. Prevention and treatment of invasive fungal infection in very low birthweight infants. Arch Dis Child Fetal Neontal Ed. 2009;94:F65–9.CrossRefGoogle Scholar
  60. 60.
    Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;59:791–3.PubMedCrossRefGoogle Scholar
  61. 61.
    Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Eng J Med. 2001;345:1660–6.CrossRefGoogle Scholar
  62. 62.
    Kaufmann D, Boryle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants < 1000 grams birth weight. J Pediatr. 2005;147:172–9.CrossRefGoogle Scholar
  63. 63.
    Manzoni P, Stolfi I, Pugni L, et al. A multi-center, randomized trial of prophylactic fluconazole in preterm neonates. N Eng J Med. 2007;256:2483–95.CrossRefGoogle Scholar
  64. 64.
    Ozturk MA, Gunes T, Kokly E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses. 2006;49:484–92.PubMedCrossRefGoogle Scholar
  65. 65.
    Howell A, Isaacs D, Halliday R. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed. 2009;94:F429–33.PubMedCrossRefGoogle Scholar
  66. 66.
    Ganesan K, Harigopal S, Neal T, et al. Prophylactic oral nystatin for preterm babies under 33 weeks gestation decreases fungal colonization and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed. 2009;94:F275–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Arrieta AC, Shea K, Dhar V, et al. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study. Clin Ther. 2010;32:265–71.PubMedCrossRefGoogle Scholar
  68. 68.
    Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J. 2009;28:840–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Megan G. Andrews
    • 1
  • Roshni Patel
    • 1
  • Jamie Miller
    • 1
    • 2
  1. 1.Department of Pharmacy: Clinical and Administrative SciencesUniversity of Oklahoma College of PharmacyOklahoma CityUSA
  2. 2.Department of PediatricsUniversity of Oklahoma College of MedicineOklahoma CityUSA

Personalised recommendations